APUS Stock Catalyst: Apimeds Pharmaceuticals US Settles Disputes and Appoints Co-CEO

May 5, 2026 · 2:07pm ET

Company resolves business combination disputes and names new leadership.

Max move

+214.2%

High of day $5.97

Sparker timei

2:07pm ET

APUS · May 5, 2026

CATALYST DATE · 1-MINUTE BARS

Catalyst Summary

Apimeds Pharmaceuticals US, Inc. (NYSE: APUS) announced on May 26, 2026, the settlement of all disputes with Inscobee regarding its business combination with MindWave Innovations. Additionally, the company appointed Sungjoon Chae as Co-CEO, effective May 4, 2026.

The settlement resolves all outstanding issues related to the business combination, allowing Apimeds to focus on its strategic initiatives. The appointment of Sungjoon Chae as Co-CEO is expected to bring new leadership and direction to the company.

This summary was generated by AI from public sources and may contain errors. Not financial advice. Trade at your own risk.

Real-time alerts

Get notified the next time APUS sparks.

Download Sniper App →

Catch the next APUS-style move in real time.

Day Trader Sniper alerts you the moment a setup like this triggers: premarket, open, or intraday.

Watch demo Download Free →